SCHEMBL19681209

SCHEMBL19681209

NCCNC(=O)C(CCCCNC(=O)C1CCCN1C(=O)Cl)NC(=O)C1CCCN1C(=O)Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTMT1 Q9BV86 2/20 0.43
APLNR P35414 1/20 0.41
SIRT6 Q8N6T7 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
OPRM1 P35372 2/20 0.39
NPFFR1 Q9GZQ6 2/20 0.39
NPFFR2 Q9Y5X5 2/20 0.39
OPRD1 P41143 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CHRNB2 P17787 5/20 0.39
CHRNB4 P30926 5/20 0.39
CHRNA3 P32297 5/20 0.39
CHRNA4 P43681 5/20 0.39
ITGB3 P05106 2/20 0.39
ITGA2B P08514 2/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2A Q12879 2/20 0.39
GRM1 Q13255 2/20 0.39
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19681283 0.96 APLNR (0.44) NTMT1APLNRSIRT6SIRT1OPRM1
SCHEMBL19681207 0.91 MMP3 (0.46) NTMT1APLNRSIRT6SIRT1OPRM1
SCHEMBL19681253 0.86 SIRT6 (0.52) NTMT1APLNRSIRT6SIRT1NPSR1
SCHEMBL21166957 0.86 ACE (0.43) NTMT1ITGB3ITGA2B
SCHEMBL21339795 0.85 MMP1 (0.45) NPSR1MMP1MMP3FKBP1A
SCHEMBL19677809 0.84 APLNR (0.52) NTMT1APLNRSIRT6SIRT1NPSR1
SCHEMBL19677785 0.84 APLNR (0.52) NTMT1APLNRSIRT6SIRT1NPSR1
SCHEMBL19677801 0.84 APLNR (0.52) NTMT1APLNRSIRT6SIRT1NPSR1
SCHEMBL19677807 0.84 APLNR (0.52) NTMT1APLNRSIRT6SIRT1NPSR1
SCHEMBL21166965 0.84 ITGB1 (0.42) NTMT1APLNRITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11707507-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid ADOCIA (FR) 2023-07-25 US disclosed
US-20200306346-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID ADOCIA (FR) 2020-10-01 US disclosed
US-20200046805-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID ADOCIA (FR) 2020-02-13 US disclosed
US-10548952-B2 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2020-02-04 US disclosed
US-10463717-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid ADOCIA (FR) 2019-11-05 US disclosed
US-20190275110-A1 COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID ADOCIA (FR) 2019-09-12 US disclosed
US-20190274953-A1 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS ADOCIA (FR) 2019-09-12 US disclosed
US-20190275108-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID ADOCIA (FR) 2019-09-12 US disclosed
US-10383918-B2 Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid ADOCIA (FR) 2019-08-20 US disclosed
US-10383920-B2 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2019-08-20 US disclosed
US-20180193421-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID ADOCIA (FR) 2018-07-12 US disclosed
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed
US-20170348394-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID ADOCIA (FR) 2017-12-07 US disclosed
US-20170348395-A1 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid ADOCIA (FR) 2017-12-07 US disclosed
US-20170348396-A1 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190275108-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID IAPP, GPR119, GLP1R NTMT1 4045/4885APLNR 18/4885SIRT6 3597/4885
US-20180193421-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID IAPP, GPR119, GIPR NTMT1 4030/4885APLNR 16/4885SIRT6 3619/4885
US-10463717-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid IAPP, GPR119, GIPR NTMT1 4114/4885APLNR 21/4885SIRT6 3364/4885
US-20200306346-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID GCG, GLP1R, GCGR NTMT1 2301/4885APLNR 543/4885SIRT6 753/4885
US-20200046805-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID IAPP, INSR, GLP1R NTMT1 3969/4885APLNR 23/4885SIRT6 3723/4885
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, IDE, INSR NTMT1 3573/4885APLNR 1847/4885SIRT6 3384/4885
US-20170348394-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID GCG, GLP1R, IAPP NTMT1 3125/4885APLNR 662/4885SIRT6 844/4885
US-10383918-B2 Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid GCG, GLP1R, IAPP NTMT1 3125/4885APLNR 662/4885SIRT6 844/4885
US-20190275110-A1 COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID GCG, GLP1R, IAPP NTMT1 2910/4885APLNR 520/4885SIRT6 913/4885
US-20170348395-A1 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid GCG, GLP1R, IAPP NTMT1 2529/4885APLNR 671/4885SIRT6 1034/4885
US-11707507-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid IAPP, INSR, GLP1R NTMT1 3969/4885APLNR 23/4885SIRT6 3723/4885
US-10383920-B2 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, IDE, INSR NTMT1 3746/4885APLNR 2130/4885SIRT6 3177/4885
US-20170348396-A1 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, F7, GIPR NTMT1 4229/4885APLNR 1129/4885SIRT6 2765/4885
US-20190274953-A1 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS GPR119, INSR, GCG NTMT1 4227/4885APLNR 389/4885SIRT6 1258/4885
US-10548952-B2 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, F7, GIPR NTMT1 4229/4885APLNR 1129/4885SIRT6 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.